Approval – Page 93 – pharmaceutical daily

March 2, 2017 Off

NICE’s approval of Merck’s Erbitux combination gives more choice for mCRC patients in England

English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.

March 2, 2017 Off

Sobi nets EMA’s approval for higher capacity drug substance for Elocta

By Dino Mustafić

Swedish Orphan Biovitrum (Sobi) has received approval from the European Medicines Agency (EMA) for the grouped type II 15 K Variation for Elocta (efmoroctocog alfa), recombinant extended half-life factor VIII Fc fusion protein product for the treatment of haemophilia A.

March 2, 2017 Off

PureTech Health gets new strategist to help CEO

By Dino Mustafić

PureTech Health has named Bharatt Chowrira as its President and Chief of Business and Strategyto work with the Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline, the company said in its annoucement on Thursday.

March 1, 2017 Off

Forward Pharma puts new CEO to reduce burn rate after $1.25 billion settlement with Biogen

By Dino Mustafić

Board of Directors has appointed its former executive vice preisdent Claus Bo Svendsen, as Chief Executive Officer, as it plans to pursue important objectives related to the the Settlement and License Agreement with Biogen.

March 1, 2017 Off

Amaran Biotechnology picks Stellar KLH for cancer vaccines

By Dino Mustafić

Stellar Biotechnologies and biopharmaceuticals manufacturer Amaran Biotechnology have entered into an exclusive multi-year supply agreement regarding studies of immunotherapies for various cancers, including breast cancer.

March 1, 2017 Off

Novartis cancer division races to catch up with rivals

By Dino Mustafić

Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview

March 1, 2017 Off

Unioversity College London develops anti-phospholipid syndrome treatment with Abzena’s technology, gets £3.5m grant from the Medical Research Council

By Dino Mustafić

A research group from University College London’s (UCL’s) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to continue developing of a new treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.

March 1, 2017 Off

Genticel, GenKyoTex to form Franco-Swiss NOX inhibitors focused Genkyotex

By Dino Mustafić

Euronext-listed Genticel and a privately-held Swiss GenKyoTex biopharmaceutical companies, will come together to become Genkyotex, a listed Franco-Swiss company whose focus will be develping a a pipeline of NOX inhibitors, a new therapeutic class in fibrosis and inflammatory pain.

March 1, 2017 Off

How These Healthcare Stocks are Faring?: Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma

By Dino Mustafić

According to Deloitte’s 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence.

March 1, 2017 Off

CPhI Istanbul rebrands and relocates into MENA region next year

By Dino Mustafić

UBM EMEA announces the rebranding and relocation of CPhI Istanbul into CPhI Middle East & Africa, which will open next year (3-5 September 2018) at ADNEC Centre, Abu Dhabi, United Arab Emirates (UAE).